Sequence: Stearyl-AGYLLGKLLOOLAAAALOOLL-NH2
| Experiment Id | EXP001411 |
|---|---|
| Paper | Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simula |
| Peptide | PepFect 14 (PF14) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Encoded by peptide:siRNA molar ratio (MR); typical MR30–MR40 |
| Rna Concentration | 50 nM (MR30) used for SGF stability testing; incubated in SGF ± pepsin before transfection |
| Mixing Ratio | PF14:siRNA molar ratio (MR) 20–40 screened; best MR depends on serum conditions |
| Formulation Format | Solid-dispersion formulation of PF14/siRNA nanocomplexes in mannitol (5%) (pre-incubated in SGF) |
| Formulation Components | PF14 + siRNA nanocomplexes dispersed in mannitol (5%) and dried (speed-vac) then reconstituted; incubated in simulated gastric fluid (pH ~1.2) ± pepsin |
| Size Nm | 149.00 |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HEK 293 luciferase-stable (human embryonic kidney) |
| Animal Model | |
| Administration Route | |
| Output Type | Luciferase knockdown after SGF incubation |
| Output Value | |
| Output Units | |
| Output Notes | Solid formulation retained most RNAi activity after 30 min in simulated gastric fluid (highly acidic), even with pepsin; longer incubations with pepsin reduced activity. |
| Toxicity Notes | |
| Curation Notes |